Royal Philips announced the successful pricing of EUR 650 million fixed rate notes due 2034 under its EMTN program, marking the healthcare industry's first EU Green Bond under the new European Green Bond Standard. The 7.8-year tranche was oversubscribed 2.7 times with a 4.0% coupon and 4.055% yield. The company maintains strong investment grade ratings across major agencies.

Royal Philips reported Q2 2026 comparable sales growth of 4% across all business segments, with group sales of EUR 4.4 billion. The company increased its Adjusted EBITA and free cash flow outlook to reflect a EUR 186 million US tariff refund benefit. Adjusted EBITA margin reached 16.4%, though excluding the tariff benefit, margins were pressured by cost inflation and higher tariffs, partially offset by productivity measures. The company reiterated its full-year 2026 comparable sales growth outlook of 3%-4.5% and raised its Adjusted EBITA margin guidance to 13.5%-14.0%.

Shandong province held its 2026 International Trade and Investment Advisors Roundtable on July 7, bringing together international advisors and representatives from over ten countries. The roundtable focused on AI-driven development, digital transformation, green manufacturing, and business environment improvements. Shandong is developing four strategic industries targeting one trillion yuan each and four emerging sectors targeting 100 billion yuan each, including AI, biomedics, and alternative energy vehicles. International companies presented forward-looking proposals on AI integration, industry transformation, and green development.

Shandong province held its 2026 International Trade and Investment Advisors Roundtable in Jinan, bringing together international advisors from over 10 countries to discuss high-level opening, digital transformation, green manufacturing, and business environment improvements. The roundtable highlighted Shandong's 15th Five-Year Plan focusing on emerging pillar industries in high-end equipment, IT services, new energy, and new materials, along with high-potential sectors in AI, biomedicine, and new energy vehicles. International companies presented proposals on AI integration with advanced manufacturing and green development initiatives.

The global Smart Hospitals Market is projected to grow from USD 90.82 billion in 2026 to USD 206.71 billion by 2032, with a CAGR of 14.56%. Growth is driven by AI integration, connected medical devices, and digital health initiatives across APAC, Europe, and North America. Key focus areas include precision medicine, operational efficiency, and cybersecurity implementation.

The global infant heart monitor market is projected to grow from USD 2.83 billion in 2025 to USD 7.93 billion by 2035, at a CAGR of 10.85%. Growth is driven by advancements in wearable medical technologies, rising adoption of remote monitoring, increased incidence of congenital heart defects, and expansion of healthcare infrastructure in emerging markets. North America leads the market while Asia-Pacific is expected to witness the fastest growth.

The global AI in Pathology market is valued at USD 28.75 Million in 2025 and expected to reach USD 68.81 Million by 2035 with a 9.12% CAGR. However, the US-Israel-Iran conflict is creating headwinds, causing IDC to revise US IT spending growth downward and disrupting cloud infrastructure and semiconductor supply chains. Despite challenges, AI infrastructure investment remains strong as enterprises seek automation solutions.

The global Medical Alert Systems Market is valued at USD 10.5 billion in 2025 and is projected to reach USD 23.5 billion by 2035, growing at a CAGR of 8.45%. Growth is driven by an aging global population and increasing preference for aging-in-place solutions. Mobile PERS systems dominate with 54.3% market share, while home-based users represent 47.7% of the market. North America leads regionally, with Asia Pacific expected to register the highest growth rates.

The global healthcare command centers market is projected to grow from USD 1.8 billion in 2024 to USD 5.0 billion by 2034, with a CAGR of 10.8%. Growth is driven by rising demand for efficient patient flow management, digital transformation in hospitals, and operational optimization. Cloud-based deployment dominates with 49% market share, while software components lead with 48% share. North America holds 41% of the global market. However, high implementation costs and limited adoption in developing regions pose challenges.

Royal Philips announced FDA 510(k) clearance for Elevate Plus, an AI-powered software suite for its EPIQ Elite and Affiniti ultrasound systems. The technology features automated measurement capabilities, workflow automation, and AI decision support for lesion classification, designed to reduce scanning time by up to 30% while maintaining clinical accuracy and helping healthcare providers manage growing demand.

Royal Philips announced on June 2, 2026, that it will issue 19,964,655 new common shares as part of its 2025 dividend distribution, with an exchange ratio of 1 new share for every 26.9341 existing shares. The dividend was calculated to be approximately EUR 0.85 per share based on a three-day volume-weighted average price of EUR 22.8640. Shareholders chose a 43.8% cash election option, with the remaining shareholders receiving shares. The total issued share capital will reach EUR 196,576,957.40 representing 982,884,787 common shares upon distribution.

The global nebulizer market is projected to grow from US$1.5 billion in 2025 to US$2.2 billion by 2032 at a CAGR of 5.9%. Growth is driven by rising respiratory disease prevalence, aging populations, technological advancements in mesh and smart nebulizers, and increasing adoption of home healthcare solutions. Key market segments include jet nebulizers, ultrasonic nebulizers, and mesh nebulizers across hospitals, clinics, and home settings.